Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis

NCT07044115 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Nephritis

Interventions

DRUG: Recombinant Humanized Monoclonal Antibody MIL62 Injection
DRUG: placebo

Sponsor

Beijing Mabworks Biotech Co., Ltd.